Entecavir for the treatment of chronic hepatitis B

Draft guidance

Committee papers (PDF 2.24 MB)

Hepatitis B - entecavir: review decision - October 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

Hepatitis B - entecavir: review proposal - July 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 74 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 138 KB)

Review decision: June 2009 information

A link to the summary of the responses from this consultation.

Appendix 1: Proposal comment summary table (PDF 28 KB)

Review proposal: May 2009 information

A full list of the organisations contacted for this review

Hepatitis B - entecavir: final appraisal determination

Hepatitis B - entecavir: final appraisal determination information

Hepatitis B - entecavir: final appraisal determination (PDF 89 KB)

Consultee and commentator comments on the ACD

Southampton Health Technology Assessment Group - ERG comments on the BMS Pharmaceuticals Ltd response to the ACD 7 May 2008

Southampton Health Technology Assessment Group - ERG comments on the BMS Pharmaceuticals Ltd response to the ACD 7 May 2008 (PDF 27 KB)

Southampton Health Technology Assessment Group - part 2

Southampton Health Technology Assessment Group - part 2 (PDF 13 KB)

Southampton Health Technology Assessment Group - part 1

Southampton Health Technology Assessment Group - part 1 (PDF 21 KB)

Roche Products

Roche Products (PDF 46 KB)

Gilead Sciences

Gilead Sciences (PDF 24 KB)

Department of Health

Department of Health (PDF 12 KB)

Royal College of Physicians

Royal College of Physicians (PDF 24 KB)

Royal College of Nursing

Royal College of Nursing (PDF 20 KB)

British Infection Society

British Infection Society (PDF 30 KB)

Bristol Myers Squibb

Bristol Myers Squibb (PDF 200 KB)

Expert comments on the ACD

Ms Penny Wilson Webb

Ms Penny Wilson Webb (PDF 45 KB)

Professor Howard Thomas

Professor Howard Thomas (PDF 18 KB)

Table of comments on the ACD

Stakeholders list - final matrix

Draft scope pre referral

Provisional matrix pre referral

Final scope

Table of comments on scope

Table of comments on matrix